Press Releases Archives | Page 59 of 116

Umoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology

June 10, 2022 By Cade Hildreth, Founder & President Leave a Comment

Partnership combines Umoja’s technologies in gene-edited iPSCs and immune differentiation for persistent anti-tumor activity with TreeFrog Therapeutics’ biomimetic platform for the mass-production of iPSC-derived cell therapies in large-scale bioreactors.

American Academy of Stem Cell Physicians To Hold Board Examination on June 18, 2022, at 2pm

June 7, 2022 By Cade Hildreth, Founder & President Leave a Comment

American Academy of Stem Cell Physicians offers Diplomat And Fellowship Certifications this June 18, 2022, in Miami!

MIAMI, June 6, 2022 – The Board of American Academy of Stem Cell Physicians is the official board certifying body of the American Academy of Stem Cell Physicians. (AASCP). As a nationally recognized academy with a mission to bring like-minded physicians together to increase awareness and education of regenerative medicine, the AASCP is proud to announce the Fellowship and Diplomat certification. [Read more…]

PolarityTE Announces FDA RMAT Awarded to Its Designation Granted to SkinTE®

May 16, 2022 By Cade Hildreth, Founder & President 1 Comment

SALT LAKE CITY, May 13, 2022 –PolarityTE, Inc. (Nasdaq: PTE) today announced that the U.S. Food and Drug Administration (FDA) granted a Regenerative Medicine Advanced Therapy (RMAT) designation to SkinTE under the Company’s open IND. [Read more…]

denovoMATRIX Launches Novel Microcarrier to Advance Cell and Gene Therapy Manufacturing

May 4, 2022 By Cade Hildreth, Founder & President Leave a Comment

DRESDEN, Germany, May. 04, 2022 — denovoMATRIX GmbH, an innovator in cell and gene therapy (CGT) manufacturing, announced the launch of a novel microcarrier for increasing access to high-quality mesenchymal stromal cells (MSCs) for stem cell-based therapies. The product, termed beadMATRIX, is designed to enable MSC proliferation and harvest in xeno-/serum-free media with high efficiency and stemness.

[Read more…]

Ncardia Launches Cellistic™, the Only iPSC-based Cell Therapy Process Development & Manufacturing Partner Purpose-built to Make Large-scale Allogeneic Cell Therapy Production a Reality Today

April 26, 2022 By Cade Hildreth, Founder & President Leave a Comment

GOSSELIES, Belgium, April 19, 2022 – Ncardia has launched a new business, Cellistic™, to focus Ncardia’s induced pluripotent stem cell (iPSC) expertise on the cell therapy development and manufacturing sector. This strategy expands on Ncardia’s existing drug discovery solutions business and capitalizes on the company’s deep expertise in iPSC differentiation and expansion to focus dedicated resources and capabilities to address the growing need for iPSC cell therapy solutions, including the development of robust cell-specific manufacturing platforms. [Read more…]